TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 11000341

Group type: EXPERIMENTAL
Intervention: Alendronate 10 mg daily plus calcium supplementation 500 mg daily
Number of subjects: 70

Group type: COMPARATOR
Intervention: Placebo plus calcium supplementation 500 mg daily
Number of subjects: 70
Study: 8976630

Group type: EXPERIMENTAL
Intervention: Aurally aided search with actual sound localization cues
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Aurally aided search with virtual sound localization cues
Number of subjects: 7

Group type: COMPARATOR
Intervention: Unaided search
Number of subjects: 7

Group type: COMPARATOR
Intervention: Visually guided search
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Synthesized three-dimensional sound cues
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Synthesized two-dimensional sound cues
Number of subjects: 7
Study: 1377290

Group type: EXPERIMENTAL
Intervention: Digital rectal examination (DRE) followed by serum PSA determination
Number of subjects: 143

Group type: COMPARATOR
Intervention: Control group (no DRE) with 2 serum PSA determinations
Number of subjects: 143
Study: 6475825

Group type: EXPERIMENTAL
Intervention: Exercise (dance exercise)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Nonexercise
Number of subjects: 0

Group type: COMPARATOR
Intervention: Baseline
Number of subjects: 0
Study: 30658603

Group type: EXPERIMENTAL
Intervention: 50,000 IU D2
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: 50,000 IU D3
Number of subjects: 100
Study: 30451595

Group type: EXPERIMENTAL
Intervention: elvitegravir/cobicistat/emtricitabine/tenofovir (EVG/COBI/FTC/TDF)
Number of subjects: 32

Group type: COMPARATOR
Intervention: EFV/FTC/TDF therapy
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Baseline sleep disordered breathing (SDB)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Respiratory Disturbance Index (RDI)
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Sleep Maintenance Efficiency, Wake after Sleep Onset, REM Sleep and RDI
Number of subjects: 32
Study: 27246120

Group type: EXPERIMENTAL
Intervention: Laparoscopic stomach-preserving surgery with sentinel basin dissection (SBD)
Number of subjects: 580

Group type: COMPARATOR
Intervention: Standard laparoscopic gastrectomy
Number of subjects: 580
Study: 24911353

Group type: EXPERIMENTAL
Intervention: M72/AS01 vaccine
Number of subjects: 37

Group type: COMPARATOR
Intervention: AS01
Number of subjects: 37

Group type: COMPARATOR
Intervention: 0.9% physiological saline
Number of subjects: 37
Study: 22882105

Group type: EXPERIMENTAL
Intervention: School health intervention program consisting of nutrition, physical activity, behavioral knowledge and skills, and social marketing.
Number of subjects: 42

Group type: COMPARATOR
Intervention: Control schools (no specific intervention mentioned).
Number of subjects: 42
Study: 20103722

Group type: EXPERIMENTAL
Intervention: High-dose celecoxib (400 mg twice daily)
Number of subjects: 204

Group type: EXPERIMENTAL
Intervention: Low-dose celecoxib (200 mg twice daily)
Number of subjects: 204

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 204
Study: 17916119

Group type: EXPERIMENTAL
Intervention: Full intervention group (n=75)
Number of subjects: 256

Group type: EXPERIMENTAL
Intervention: Minimal intervention group (n=75)
Number of subjects: 256

Group type: COMPARATOR
Intervention: Control group (n=75)
Number of subjects: 256

Group type: EXPERIMENTAL
Intervention: Referred patients with major or minor depression (n=37)
Number of subjects: 256

Group type: EXPERIMENTAL
Intervention: Nondepressed patients (n=180)
Number of subjects: 256
Study: 17505380

Group type: EXPERIMENTAL
Intervention: Fentanyl HCl iontophoretic transdermal system (ITS)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard regimen of morphine provided by an intravenous patient-controlled analgesia (IV PCA) pump
Number of subjects: 0
Study: 15040557

Group type: EXPERIMENTAL
Intervention: CV8 (dihydroartemisinin/piperaquine/trimethoprim/primaquine 256/2560/720/40 mg)
Number of subjects: 165

Group type: COMPARATOR
Intervention: Malarone (atovaquone/proguanil 3000/1200 mg)
Number of subjects: 165

Group type: EXPERIMENTAL
Intervention: CV8
Number of subjects: 165

Group type: COMPARATOR
Intervention: Malarone
Number of subjects: 165
Study: 11315718

Group type: EXPERIMENTAL
Intervention: CMF chemotherapy regimens (Cyclophosphamide, Methotrexate, 5-Fluorouracil)
Number of subjects: 0
Study: 9253783

Group type: EXPERIMENTAL
Intervention: Weekly dosing of epoetin alfa
Number of subjects: 0

Group type: COMPARATOR
Intervention: Daily dosing of epoetin alfa
Number of subjects: 0
Study: 8416444

Group type: EXPERIMENTAL
Intervention: Single 2-g dose of ampicillin
Number of subjects: 84

Group type: COMPARATOR
Intervention: Cephalosporin (control)
Number of subjects: 84
Study: 3940480

Group type: EXPERIMENTAL
Intervention: Prednisolone, 60 mg/d for 2 weeks, then 30 mg/d for another 2 weeks
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study: 31225897

Group type: EXPERIMENTAL
Intervention: Computer‐facilitated screening and brief intervention (CSBI)
Number of subjects: 965

Group type: COMPARATOR
Intervention: Usual Care (UC)
Number of subjects: 965
Study: 28123163

Group type: EXPERIMENTAL
Intervention: Rivaroxaban 15 mg twice daily for 21 days during acute treatment phase
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Rivaroxaban 20 mg once daily for up to 12 months after initial treatment
Number of subjects: 0
Study: 26564581

Group type: EXPERIMENTAL
Intervention: Expiratory Muscle Strength Training (STU)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Control Group (CON)
Number of subjects: 29
Study: 25071062

Group type: EXPERIMENTAL
Intervention: Web-based decision aid
Number of subjects: 220

Group type: EXPERIMENTAL
Intervention: Leaflet
Number of subjects: 220

Group type: COMPARATOR
Intervention: Usual practice
Number of subjects: 220
Study: 22525171

Group type: EXPERIMENTAL
Intervention: Patching therapy (1 hour daily per month of age until 8 months, then 50% of waking hours)
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: Patching therapy
Number of subjects: 104
Study: 19544315

Group type: EXPERIMENTAL
Intervention: Fluoxetine or Nortriptyline
Number of subjects: 195
Study: 17513629

Group type: EXPERIMENTAL
Intervention: Magnesium sulfate 4 g IV
Number of subjects: 200

Group type: COMPARATOR
Intervention: Physiological saline (placebo)
Number of subjects: 200
Study: 15343256

Group type: EXPERIMENTAL
Intervention: Recombinant FSH with Ganirelix
Number of subjects: 54

Group type: COMPARATOR
Intervention: Recombinant FSH without Ganirelix
Number of subjects: 54
Study: 11593124

Group type: EXPERIMENTAL
Intervention: Hydrolyzed formula
Number of subjects: 36

Group type: COMPARATOR
Intervention: Standard formula
Number of subjects: 36
Study: 9677506

Group type: EXPERIMENTAL
Intervention: Acetyl L-carnitine (ALC)
Number of subjects: 334

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 334
Study: 8053025

Group type: EXPERIMENTAL
Intervention: Oral artemisinin derivatives in combination with mefloquine for primary treatment of uncomplicated malaria
Number of subjects: 1000

Group type: EXPERIMENTAL
Intervention: Oral artemisinin derivatives for treatment of recrudescent infections
Number of subjects: 1000

Group type: EXPERIMENTAL
Intervention: Oral artemisinin derivatives for patients with high parasitaemias (> or = 4%) but no clinical evidence of severity
Number of subjects: 1000

Group type: EXPERIMENTAL
Intervention: Parenteral formulation of artemether given rectally
Number of subjects: 1000
Study: 3381781

Group type: EXPERIMENTAL
Intervention: Pyrethrins combined with piperonyl butoxide (RID)
Number of subjects: 58

Group type: COMPARATOR
Intervention: 1% permethrin (NIX)
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: RID comb
Number of subjects: 58
Study: 31796700

Group type: EXPERIMENTAL
Intervention: Tetrax biofeedback balance training for 30 min/day for 2 weeks (10 sessions)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Conventional balance training for 30 min/day for 2 weeks (10 sessions)
Number of subjects: 20
Study: 28185886

Group type: EXPERIMENTAL
Intervention: Macronutrient intake (dietary monitoring)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Dietary monitoring with individualized feedback
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Optimizing intake of macronutrients (fat and protein)
Number of subjects: 75
Study: 26059002

Group type: EXPERIMENTAL
Intervention: WaySafe
Number of subjects: 1393

Group type: COMPARATOR
Intervention: Treatment as Usual (TAU)
Number of subjects: 1393
Study: 23370209

Group type: EXPERIMENTAL
Intervention: Casting-type calcifications
Number of subjects: 0
Study: 22103965

Group type: EXPERIMENTAL
Intervention: Triclosan coated polydioxanone sutures
Number of subjects: 750

Group type: COMPARATOR
Intervention: Standard polydioxanone sutures
Number of subjects: 750
Study: 20122026

Group type: EXPERIMENTAL
Intervention: Involvement of primary care physicians (PCPs) in care discussions and decision-making
Number of subjects: 357

Group type: EXPERIMENTAL
Intervention: Perceived involvement of PCPs
Number of subjects: 357

Group type: EXPERIMENTAL
Intervention: Oncologists' beliefs about PCP involvement
Number of subjects: 357

Group type: EXPERIMENTAL
Intervention: Differences in PCP involvement for older vs younger patients
Number of subjects: 357

Group type: EXPERIMENTAL
Intervention: PCP involvement in advanced cancer care
Number of subjects: 357
Study: 17259205

Group type: EXPERIMENTAL
Intervention: Lorazepam
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 14752069

Group type: COMPARATOR
Intervention: Short chemotherapy (6 months)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Long chemotherapy (15 months)
Number of subjects: 40
Study: 15363236

Group type: EXPERIMENTAL
Intervention: Autografts of patellar bone-tendon-bone (B-PT-B) and 4 strands of semitendinosus/gracilis
Number of subjects: 53

Group type: COMPARATOR
Intervention: Allografts of B-PT-B, 4 strands of semitendinosus/2 strands of gracilis tendons, double tibialis posterior, and Achilles bone-tendon
Number of subjects: 53
Study: 10691155

Group type: EXPERIMENTAL
Intervention: Acarbose (100 mg t.d.s.)
Number of subjects: 75

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 75
Study: 9090332

Group type: EXPERIMENTAL
Intervention: High-dose olanzapine
Number of subjects: 335

Group type: EXPERIMENTAL
Intervention: Olanzapine
Number of subjects: 335

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 335

Group type: COMPARATOR
Intervention: Haloperidol (10-20 mg/day)
Number of subjects: 335
Study: 1439601

Group type: EXPERIMENTAL
Intervention: Extracorporeal shock wave lithotripsy (ESWL)
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Percutaneous nephrolithotomy (PNL)
Number of subjects: 55

Group type: COMPARATOR
Intervention: Cost comparison
Number of subjects: 55
Study: 2945785

Group type: EXPERIMENTAL
Intervention: Calcium (1 g elemental calcium/day)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 54
Study: 29536776

Group type: EXPERIMENTAL
Intervention: Reiki
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Physiotherapy
Number of subjects: 60

Group type: COMPARATOR
Intervention: Drug therapy
Number of subjects: 60
Study: 27762575

Group type: EXPERIMENTAL
Intervention: Wise deliberate practice interventions
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control condition teaching standard study skills
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control condition discussing deep interests, generalized motivation, and high achievement
Number of subjects: 0
Study: 24351126

Group type: EXPERIMENTAL
Intervention: Caregiver pairs
Number of subjects: 304

Group type: EXPERIMENTAL
Intervention: Emotional, financial, and physical quality of life
Number of subjects: 304

Group type: EXPERIMENTAL
Intervention: Emotional and financial quality of life
Number of subjects: 304

Group type: EXPERIMENTAL
Intervention: Social support
Number of subjects: 304

Group type: COMPARATOR
Intervention: Solo caregivers
Number of subjects: 304
Study: 23043272

Group type: EXPERIMENTAL
Intervention: Minimally invasive surgery (MIS)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Conventional surgery (CON)
Number of subjects: 40
Study: 21114221

Group type: EXPERIMENTAL
Intervention: Continuous blood gas monitoring with the CDI 500
Number of subjects: 100

Group type: COMPARATOR
Intervention: Standard CPB blood gas management with intermittent blood gas results (Control)
Number of subjects: 100
Study: 18451005

Group type: EXPERIMENTAL
Intervention: Olanzapine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Perphenazine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Clozapine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Quetiapine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Risperidone
Number of subjects: 0

Group type: COMPARATOR
Intervention: Ziprasidone
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Clozapine (in phase 2)
Number of subjects: 0
Study: 15775951

Group type: EXPERIMENTAL
Intervention: Reminder by telephone
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Reminder by mail
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Reminder by SMS
Number of subjects: 0

Group type: COMPARATOR
Intervention: No reminder (Control)
Number of subjects: 0
Study: 14516890

Group type: EXPERIMENTAL
Intervention: Aspirin 160 mg/day
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Aspirin 75 mg/day + warfarin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Warfarin alone
Number of subjects: 0
Study: 10332684

Group type: COMPARATOR
Intervention: lispro (group 2)
Number of subjects: 24

Group type: COMPARATOR
Intervention: lispro + NPH (group 3)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Hum-R (group 1)
Number of subjects: 24
Study: 8711985

Group type: EXPERIMENTAL
Intervention: Sodium valproate
Number of subjects: 56
Study: 1776541

Group type: EXPERIMENTAL
Intervention: Smelling a preload
Number of subjects: 0

Group type: COMPARATOR
Intervention: No preload
Number of subjects: 0
Study: 6810866

Group type: EXPERIMENTAL
Intervention: Lithicarb (standard lithium carbonate preparation)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Priadel (sustained-release lithium carbonate preparation)
Number of subjects: 6
Study: 30635252

Group type: EXPERIMENTAL
Intervention: 6 + 10 group (PCV10 at 6 weeks and 10 weeks of age)
Number of subjects: 304

Group type: COMPARATOR
Intervention: 6 + 14 group (PCV10 at 6 weeks and 14 weeks of age)
Number of subjects: 304

Group type: EXPERIMENTAL
Intervention: Post-booster response at 10 months of age
Number of subjects: 304

Group type: EXPERIMENTAL
Intervention: 6 + 10 group
Number of subjects: 304

Group type: COMPARATOR
Intervention: 6 + 14 group
Number of subjects: 304
Study: 28474817

Group type: EXPERIMENTAL
Intervention: Diabetic patients (DM)
Number of subjects: 792

Group type: EXPERIMENTAL
Intervention: Insulin-treated DM (ITDM)
Number of subjects: 792

Group type: COMPARATOR
Intervention: Non-insulin-treated DM (NITDM)
Number of subjects: 792
Study: 25934656

Group type: EXPERIMENTAL
Intervention: Medical therapy plus stenting
Number of subjects: 380

Group type: COMPARATOR
Intervention: Best medical therapy alone
Number of subjects: 380
Study: 23296149

Group type: EXPERIMENTAL
Intervention: Anti-CD25 monoclonal antibody (mAb) therapy
Number of subjects: 15

Group type: COMPARATOR
Intervention: CNI (Control group)
Number of subjects: 15
Study: 20818996

Group type: EXPERIMENTAL
Intervention: Liquid nitrogen cryotherapy (LN)
Number of subjects: 65
Study: 20042790

Group type: EXPERIMENTAL
Intervention: Left arm activation training (20-30 hours)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Traditional visual scanning training (10 hours)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Both groups (Left arm activation and Traditional visual scanning)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Left arm activation training
Number of subjects: 12
Study: 17896565

Group type: EXPERIMENTAL
Intervention: docetaxel/prednisone
Number of subjects: 0

Group type: COMPARATOR
Intervention: mitoxantrone/prednisone
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: satraplatin
Number of subjects: 0
Study: 15133973

Group type: EXPERIMENTAL
Intervention: Axial alignment measurement using computer tomography
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Rotational alignment measurement using four angles: proximal femoral, distal femoral, proximal tibial, and ankle joint angles
Number of subjects: 50
Study: 12043861

Group type: EXPERIMENTAL
Intervention: Vertical gutta-percha condensation technique
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Lateral gutta-percha condensation technique
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Both techniques
Number of subjects: 0
Study: 9827976

Group type: EXPERIMENTAL
Intervention: Topical oral r‐metHuG‐CSF (filgrastim) administered as a viscous mouthrinse (carboxymethylcellulose 2%, oleum citrii) 4 x 120 microg/day from days 10 to 16.
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Topical oral r‐metHuG‐CSF (filgrastim)
Number of subjects: 8
Study: 7986112

Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapy with increased dose intensity
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Adjuvant/neoadjuvant chemotherapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard adjuvant/neoadjuvant chemotherapy regimens
Number of subjects: 0
Study: 2506834

Group type: EXPERIMENTAL
Intervention: Intraportal chemotherapy with 30 mg of Mitomycin-C (in 3 doses) and 5 mg/kg/day of 5-FU (1985-1986) or 3 mg/kg/day of 5-FU (1987-1988)
Number of subjects: 51

Group type: COMPARATOR
Intervention: Control group with the same doses of drugs injected into the peripheral vein
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Intraportal chemotherapy with 5 mg/kg/day of 5-FU
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Intraportal chemotherapy with 3 mg/kg/day of 5-FU
Number of subjects: 51

Group type: COMPARATOR
Intervention: Both groups
Number of subjects: 51
Study: 1277718

Group type: EXPERIMENTAL
Intervention: Hydrocortisone sodium phosphate
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Hydrocortisone sodium succinate
Number of subjects: 24
Study: 7304488

Group type: EXPERIMENTAL
Intervention: Single dose of piperazine citrate administered twice within a 2-week period
Number of subjects: 185

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 185

Group type: EXPERIMENTAL
Intervention: Single dose of piperazine citrate
Number of subjects: 185
Study: 30119098

Group type: EXPERIMENTAL
Intervention: Oral hygiene and cosmetic products (toothpastes, dental tablets, mouthwashes, lip-balms, lipsticks)
Number of subjects: 66
Study: 29443750

Group type: EXPERIMENTAL
Intervention: roflumilast 500 μg once daily for 12 months
Number of subjects: 120

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: roflumilast
Number of subjects: 120
Study: 26640805

Group type: EXPERIMENTAL
Intervention: CSII + Lira
Number of subjects: 39

Group type: COMPARATOR
Intervention: CSII alone
Number of subjects: 39
Study: 24096366

Group type: EXPERIMENTAL
Intervention: Mindfulness-based stress reduction (MBSR)
Number of subjects: 149

Group type: EXPERIMENTAL
Intervention: Exercise
Number of subjects: 149

Group type: COMPARATOR
Intervention: Control (waitlist)
Number of subjects: 149

Group type: EXPERIMENTAL
Intervention: Overall population
Number of subjects: 149
Study: 22154766

Group type: EXPERIMENTAL
Intervention: Metformin, 2,000 mg/daily
Number of subjects: 132

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 132
Study: 21055319

Group type: EXPERIMENTAL
Intervention: Subcutaneous immunotherapy (SCIT)
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Sublingual immunotherapy (SLIT)
Number of subjects: 160

Group type: COMPARATOR
Intervention: SCIT
Number of subjects: 160

Group type: COMPARATOR
Intervention: SLIT
Number of subjects: 160
Study: 17350152

Group type: EXPERIMENTAL
Intervention: Sugar-free chewing gum with lactoperoxidase (LP)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Sugar-free chewing gum with micro granules of silicon dioxide (SD)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Sugar-free chewing gum with zinc gluconate (ZG)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Additive-free (AF) gum
Number of subjects: 12
Study: 14560075

Group type: EXPERIMENTAL
Intervention: Light mobilization program (intervention group)
Number of subjects: 457

Group type: COMPARATOR
Intervention: Control group (primary health care treatment)
Number of subjects: 457

Group type: EXPERIMENTAL
Intervention: Intervention group
Number of subjects: 457

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 457

Group type: EXPERIMENTAL
Intervention: Economic returns of the intervention
Number of subjects: 457
Study: 10693636

Group type: EXPERIMENTAL
Intervention: Heat-treated donor spleen cells
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 9112348

Group type: EXPERIMENTAL
Intervention: Three pretransplant transfusions
Number of subjects: 423

Group type: COMPARATOR
Intervention: No transfusions (control group)
Number of subjects: 423
Study: 8227758

Group type: EXPERIMENTAL
Intervention: CBZ low (15‐25 mumol/l)
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: CBZ high (28‐40 mumol/l)
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: LI (0.6‐0.8 mumol/l)
Number of subjects: 84
Study: 3512121

Group type: EXPERIMENTAL
Intervention: Captopril
Number of subjects: 50
Study: 28253878

Group type: EXPERIMENTAL
Intervention: Kampo education introduction into clinical training
Number of subjects: 888

Group type: COMPARATOR
Intervention: Kampo education availability
Number of subjects: 888

Group type: COMPARATOR
Intervention: Kampo education methods
Number of subjects: 888

Group type: EXPERIMENTAL
Intervention: Residents' interest in Kampo medicine
Number of subjects: 888

Group type: EXPERIMENTAL
Intervention: Perceived value of learning Kampo medicine
Number of subjects: 888

Group type: EXPERIMENTAL
Intervention: Satisfaction with training
Number of subjects: 888

Group type: EXPERIMENTAL
Intervention: Desire to learn Kampo medicine
Number of subjects: 888

Group type: EXPERIMENTAL
Intervention: Integration of Western and Kampo medicine
Number of subjects: 888

Group type: EXPERIMENTAL
Intervention: Prescription of Kampo medicine
Number of subjects: 888

Group type: EXPERIMENTAL
Intervention: Reluctance to prescribe after residency
Number of subjects: 888
Study: 26448147

Group type: EXPERIMENTAL
Intervention: IL–1 receptor antagonist IL‐1Ra (anakinra)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study: 23557450

Group type: EXPERIMENTAL
Intervention: Brief educational intervention at the time of diagnosis
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (no intervention specified)
Number of subjects: 0